Croatia Joins European Medicines Network
Europe prepares for inclusion of Croatia in EMA activities.
Croatia joined the European Union on July 1, 2013 and, therefore, became part of the European Medicines Network. The country will now be involved in European Medicines Agency (EMA) activities. Europe began preparing for Croatia’s participation in 2007 with the creation of the Instrument for Pre-accession Assistance (IPA) program and with ongoing work with Croatian authorities. Croatia participated in selected EMA meetings as part of the IPA program.
EMA and Croatia also started a pre-accession linguistic review of product information in January 2011 to facilitate “the phasing-in of European Commission decisions on centrally authorised medicines once Croatia joined the EU thereby avoiding delays in the supply of medicines in Croatia.” EMA has issued revised guidance that outlines the phasing-in of authorized products in Croatia and operational aspects.
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
